Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**WeiLeShu** is an orally administered probiotic supplement developed and manufactured by Tongchuang Biotechnology. The product contains approximately 6 billion live probiotic organisms and has been reported to consist mainly of *Lactobacillus helveticus* and *Bifidobacterium longum*; strain-level identities and the complete formulation have not been publicly elucidated. It is intended to modulate gastrointestinal microbiota, support intestinal barrier function, and potentially exert anti-inflammatory and immunomodulatory effects. WeiLeShu was evaluated as an adjunct to systemic therapy in a randomized phase 2 study in metastatic colorectal cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WeiLeShu.